Osteoporosis is a major public health problem but is underdiagnosed and undertreated. A new randomized controlled trial indicates that population screening for osteoporosis by BMD assessment resulted in improved treatment and reduced risk of fractures in postmenopausal women.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marshall, D., Johnell, O. & Wedel, H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312, 1254–1259 (1996).
Delmas, P. D. Treatment of postmenopausal osteoporosis. Lancet 359, 2018–2026 (2002).
Barr, R. J., Stewart, A., Torgerson, D. J. & Reid, D. A. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos. Int. doi:010.1007/s00198-009-10072011x.
Food and Drug Administration. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis [online], (1994).
US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann. Intern. Med. 137, 526–528 (2002).
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation [online], (2008).
Dell, R., Green, D., Schelkun, S. R. & Williams, K. Osteoporosis disease management: the role of the orthopedic surgeon. J. Bone Joint Surg. Am. 90 (Suppl. 4), 188–194 (2008).
Newman, E. D., Ayoub, W. T., Starkey, R. H., Diehl, J. M. & Wood, G. C. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenpausal women after 5 years. Osteoporos. Int. 14, 146–151 (2003).
Kanis, J. A. & World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Healthcare Level (WHO, Sheffield, 2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
In the past year, the author has received honoraria for lectures from the following companies: Amgen, Novartis, Procter & Gamble and sanofi-aventis; and consulting fees from the following companies: Amgen, Baxter, Eli Lilly, InteKrin, Johnson & Johnson, MannKind, Novartis, Novo Nordisk, Procter & Gamble, sanofi-aventis and Takeda Pharmaceuticals. Through his University, he has research support from the following companies: Amgen, Eli Lilly, Merck, Novartis, Ortho-McNeil Janssen and Procter & Gamble.
Rights and permissions
About this article
Cite this article
Watts, N. Bone density screening leads to reduced fracture risk. Nat Rev Endocrinol 6, 17–18 (2010). https://doi.org/10.1038/nrendo.2009.246
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.246
This article is cited by
-
siRNA Knock-Down of RANK Signaling to Control Osteoclast-Mediated Bone Resorption
Pharmaceutical Research (2010)
